Kevin Boyle Senior: Certainly, Prakhar. So our cash runway is still into the second quarter of 2023, and as a biotech, we are always exploring financing options. There is great interest based on this encouraging early data, which is giving us a lot of flexibility and options available to us. We appreciate our supportive and loyal shareholder base, and have also been experiencing a lot of interest from new prospective investors who see the potential and power of our TCR-T cell therapy. Reminder, we do have the ATM in place. So that’s yet another option in addition to we worked very hard earlier this year to have the shelf in place as well. So we have many different options and have teed ourselves up to be able to fund raise in any number of fashions. So we are very confident in our ability to expand our cash runway and look forward to providing updates in the future.
Prakhar Agrawal: Thank you.
Kevin Boyle Senior: Thank you.
Operator: Our next question comes from the line of James Shin with Wells Fargo. Your line is now open.
James Shin: Hey. Good morning, guys. Thanks for taking my question. Just want to go back to patient number one real quick. It sounds like you are still doing work on things and it sounds like HLA and G12D were still present, tumor looks great. So will you be looking at any exhaustion signals suggest that maybe that’s why the response is going to persist? And then related, when you guys move to the cryopreserved product, can you say what sort of changes you saw from the freeze process relative to the current warm cells?
Drew Deniger: Yeah. Thanks, James. Drew here. Good morning. I will take the first one and then kick over to Abhi for the manufacturing question. So in regards to patient one, we are very encouraged with the target still there, very encouraged that the T cells are infiltrating into the tumor. We are looking at exhaustion markers and they are — because we actually have some of the cells that are alive from that tumor we look at their ability to be responsive to not only to mutation, but kind of a vitro tumor system. So we are looking at all that. We are quite encouraged and when to use the clinical data that we get to drive maybe kind of hypotheses around what’s going on in the clinical setting. So I am going to kick it over to Abhi for the cryopreserved question.
Abhi Srivastava: Yeah. Thanks, Drew. I want to start by saying that our manufacturing platform is very robust and reproducible. We have been able to produce high purity, high viability and high TCR positivity cell product. When it comes to moving from fresh to cryopreserve product, there’s not many — there is not any change in our overall manufacturing process, except we have just added a formulation, cryopreserve in the formulation. And we have done a process qualification run and based on that we can say that our overall manufacturing process is very similar to what we have as a fresh product.
James Shin: Thanks, guys. Appreciate it.
Kevin Boyle Senior: Thanks, James.
Operator: Our next question comes from the line of Chris Howerton with Jefferies. Your line is now open. Chris, you may be on mute.
Unidentified Company Representative: We can move to the next caller, Liz.
Operator: Our next question comes from the line of Yale Jen with Laidlaw. Your line is now open.
Yale Jen: Hello?
Kevin Boyle Senior: Good morning, Yale.
Yale Jen: Hey. Sorry. I didn’t hear my name. I was just. My first question is — thanks for taking the question. My first question is that the next patient and you mentioned that will be the second dose level. We you listed the last patient was 54 billion cells. How should we think about the next one, would that be in the same ballpark or — and then I have a follow-up question.